Next generation immunotherapeutics-honing the magic bullet

Current Opinion in Biotechnology

Volumn 20, Issue 4, 2009, Pages 405-411

  Enever, Carrie ^a   Batuwangala, Thil ^a   Plummer, Chris ^a   Sepp, Armin ^a  

^a Domantis Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; IMMUNOTHERAPEUTICS; INFLAMMATORY DISEASE; MAGIC BULLETS; SIGNALLING PATHWAYS; THERAPEUTIC ANTIBODIES;

MONOCLONAL ANTIBODIES;

ALX 0081; ALX 0681; AMG 220; ART 621; BEVACIZUMAB; BLINATUMOMAB; C 326; CATUMAXOMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; CT 322; EPRATUZUMAB; ERTUMAXOMAB; ESBA 105; GSK 182771; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MT 110; RANIBIZUMAB; RITUXIMAB; RM 28; SBI 087; TRU 015; TRU 016; UNCLASSIFIED DRUG; VB 6 845;

ANTIBODY ENGINEERING; ARTHRITIS; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER IMMUNOTHERAPY; CARCINOMATOUS PERITONITIS; CATARACT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATORY DISEASE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MONOTHERAPY; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; UVEITIS;

ANTIBODY SPECIFICITY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY;

EID: 70349758454     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2009.07.002     Document Type: Review

References (60)

1. Todd P.A., and Brogden R.N. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 37 (1989) 871-899
2. Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986) 522-525
3. McCafferty J., Griffiths A.D., Winter G., and Chiswell D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348 (1990) 552-554
4. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., and Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 222 (1991) 581-597
5. Jakobovits A., Amado R.G., Yang X., Roskos L., and Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25 (2007) 1134-1143
6. Gaudreault J., Fei D., Rusit J., Suboc P., and Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46 (2005) 726-733
7. Kowalski M., Brazas L., Zaretsky R., Rasamoelisolo M., MacDonald G., Cuthbert W., and Glover N. A phase I study of VB6-845, an anti-EpCAM fusion protein targeting advanced solid tumours of epithelial origin: preliminary results. J Clin Oncol (Meeting Abstracts) 26 (2008) 14663
8. Rader C. Overview on concepts and applications of Fab antibody fragments. Curr Protoc Protein Sci 55 (2009) 6.9.1-6.9.14
9. Choy E.H.S., Hazleman B., Smith M., Moss K., Lisi L., Scott D.G.I., Patel J., Sopwith M., and Isenberg D.A. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 41 (2002) 1133-1137
10. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54 (2002) 531-545
11. Ottiger M., Thiel M.A., Feige U., Lichtlen P., and Urech D.M. Efficient intraocular penetration of topical anti-TNF-a single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci 50 (2009) 779-786. Convincing demonstration that a scFv-based protein therapeutic be applied topically to the eye, where it reaches therapeutically useful concentrations and displays acceptable rate of clearance.
12. Zhao X., Lapalombella R., Joshi T., Cheney C., Gowda A., Hayden-Ledbetter M.S., Baum P.R., Lin T.S., Jarjoura D., Lehman A., et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110 (2007) 2569-2577
13. Vaughan T.J., Osbourn J.K., and Tempest P.R. Human antibodies by design. Nat Biotechnol 16 (1998) 535-539
14. Holt L.J., Herring C., Jespers L.S., Woolven B.P., and Tomlinson I.M. Domain antibodies: proteins for therapy. Trends Biotechnol 21 (2003) 484-490
15. Revets H., De Baetselier P., and Muyldermans S. Nanobodies as novel agents for cancer therapy. Exp Opin Biol Ther 5 (2005) 111-124
16. Nuttall S.D., Krishnan U.V., Hattarki M., De Gori R., Irving R.A., and Hudson P.J. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol 38 (2001) 313-326
17. Ewert S., Huber T., Honegger A., and Pluckthun A. Biophysical properties of human antibody variable domains. J Mol Biol 325 (2003) 531-553
18. Dumoulin M., Conrath K., Van Meirhaeghe A., Meersman F., Heremans K., Frenken L.G., Muyldermans S., Wyns L., and Matagne A. Single-domain antibody fragments with high conformational stability. Protein Sci 11 (2002) 500-515
19. Riechmann L., and Muyldermans S. Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods 231 (1999) 25-38
20. Jespers L., Schon O., Famm K., and Winter G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 22 (2004) 1161-1165. Significant improvements made to the biophysical properties of human VH domain antibodies by subjecting the combinatorial phage display libraries to preselection for the refolding of the antibody domains following denaturation at 80°C.
21. Vincke C., Loris R., Saerens D., Martinez-Rodriguez S., Muyldermans S., and Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284 (2009) 3273-3284. Thorough biochemical and biophysical analysis of the effects that camelid VHH domain hallmark mutations have on the nanobody activity and stability.
22. Desmyter A., Spinelli S., Payan F., Lauwereys M., Wyns L., Muyldermans S., and Cambillau C. Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology. J Biol Chem 277 (2002) 23645-23650
23. Chen W., Zhu Z., Feng Y., and Dimitrov D.S. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci 105 (2008) 17121-17126. HIV gp120 is a notoriously difficult target for therapeutic antibodies because the IgG-accessible residues mutate easily. Their small size allows dAbs to reach a conserved epitope that is inaccessible to full antibodies.
24. Coppieters K., Dreier T., Silence K., de Haard H., Lauwereys M., Casteels P., Beirnaert E., Jonckheere H., Van de Wiele C., Staelens L., et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 54 (2006) 1856-1866. A bispecific array of tandem VHH domains is assembled to achieve very high target-binding activity and enhanced serum half-life through serum albumin-binding activity.
25. Holt L.J., Basran A., Jones K., Chorlton J., Jespers L.S., Brewis N.D., and Tomlinson I.M. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Select 21 (2008) 283-288. An albumin-binding Vk dAb is used to extend the serum half-life of IL-1ra, a potent anti-rheumatic.
26. Dennis M.S., Zhang M., Meng Y.G., Kadkhodayan M., Kirchhofer D., Combs D., and Damico L.A. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277 (2002) 35035-35043
27. Fiedler M., and Skerra A. Non-antibody scaffolds. In: Dübel P.D.S. (Ed). Handbook of Therapeutic Antibodies (2008) 467-499
28. Getmanova E.V., Chen Y., Bloom L., Gokemeijer J., Shamah S., Warikoo V., Wang J., Ling V., and Sun L. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 13 (2006) 549-556. The first entirely in vitro selected and affinity matured immunotherapeutic to enter clinical trials, based on the alternative scaffold of the human fibronectin domain.
29. Lipovsek D., and Pluckthun A. In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 290 (2004) 51-67
30. Dineen S.P., Sullivan L.A., Beck A.W., Miller A.F., Carbon J.G., Mamluk R., Wong H., and Brekken R.A. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8 (2008) 352
31. Sweeney C.J., Chriorean E.G., Mita M.M., Papadopoulos K.P., Silver B., Freed M., Gokemeijer J., Eaton C., Furfine E., and Tolcher A.W. Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). J Clin Oncol (Meeting Abstracts) 26 (2008) 3523
32. Silverman J., Liu Q., Bakker A., To W., Duguay A., Alba B.M., Smith R., Rivas A., Li P., Le H., et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23 (2005) 1556-1561. Reports a novel cysteine-rich alternative scaffold of A-domains has been assembled into high-avidity bispecific tandem array capable of binding IL-6 for the therapeutic effect and the Fc-region of human immunoglobulins for improving pharmacokinetics.
33. Braddock M. 11th annual inflammatory and immune diseases drug discovery and development summit. Exp Opin Invest Drugs 16 (2007) 909-917
34. Binz H.K., Stumpp M.T., Forrer P., Amstutz P., and Pluckthun A. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 332 (2003) 489-503. An excellent example of sequence-based and structure-based approach to protein design with a potential to deliver well-expressed high-affinity immunotherapeutics.
35. Zahnd C., Wyler E., Schwenk J.M., Steiner D., Lawrence M.C., McKern N.M., Pecorari F., Ward C.W., Joos T.O., and Pluckthun A. A designed ankyrin repeat protein evolved to picomolar affinity to her2. J Mol Biol 369 (2007) 1015-1028. A therapeutically useful DARPin is cloned by ribosome display and affinity matured to clinically useful range.
36. Binz H.K., Amstutz P., Kohl A., Stumpp M.T., Briand C., Forrer P., Grutter M.G., and Pluckthun A. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22 (2004) 575-582
37. Dall'Acqua W.F., Kiener P.A., and Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281 (2006) 23514-23524. Systematic approach to improving the Fc fragment binding to FcRn delivers immunoglobulin variants with improved half-lives.
38. Oganesyan V., Damschroder M.M., Woods R.M., Cook K.E., Wu H., and Dall'acqua W.F. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 46 (2009) 1750-1755
39. Datta-Mannan A., Witcher D.R., Tang Y., Watkins J., and Wroblewski V.J. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 282 (2007) 1709-1717
40. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103 (2006) 4005-4010. Computational design of Fc fragments with enhanced ADCC-properties for improved effector functions against cells expressing low levels of target antigen.
41. Natsume A., In M., Takamura H., Nakagawa T., Shimizu Y., Kitajima K., Wakitani M., Ohta S., Satoh M., Shitara K., et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 68 (2008) 3863-3872
42. Klein B., and Gottfried M. Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab. J Buon 12 Suppl 1 (2007) S127-S136
43. Lee J.J., and Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 13 (2007) 276-281
44. Leonard J.P., Schuster S.J., Emmanouilides C., Couture F., Teoh N., Wegener W.A., Coleman M., and Goldenberg D.M. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 113 (2008) 2714-2723
45. Kufer P., Lutterbuse R., and Baeuerle P.A. A revival of bispecific antibodies. Trends Biotechnol 22 (2004) 238-244
46. Wu C., Ying H., Grinnell C., Bryant S., Miller R., Clabbers A., Bose S., McCarthy D., Zhu R.R., Santora L., et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25 (2007) 1290-1297. Successful design of a bispecific monoclonal antibody where the second binding site is inserted by fusing a second set of variable domains to the light and heavy chain N-termini of an IgG mAb.
47. Shen J., Vil M.D., Jimenez X., Iacolina M., Zhang H., and Zhu Z. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 281 (2006) 10706-10714
48. Hsieh C-M, McRae BL, Kutskova Y, Memmott J, Roguska M, Tomlinson I, Tuna M, Grant S, Enever C: Dual-specific IL-1a/IL-1b antibodies. US Patent 2007, WO2008082651.
49. Wolf E., Hofmeister R., Kufer P., Schlereth B., and Baeuerle P.A. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 10 (2005) 1237-1244
50. Haas C., Krinner E., Brischwein K., Hoffmann P., Lutterbüse R., Schlereth B., Kufer P., and Baeuerle P.A. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214 (2009) 441-453
51. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321 (2008) 974-977. A landmark paper of the therapeutic success of the first T-cell engaging BiTE antibody.
52. Tanaka T., Williams R.L., and Rabbitts T.H. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 26 (2007) 3250-3259
53. Dekker S., Toussaint W., Panayotou G., de Wit T., Visser P., Grosveld F., and Drabek D. Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses. J Virol 77 (2003) 12132-12139
54. Abulrob A., Sprong H., Van Bergen en Henegouwen P., and Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 95 (2005) 1201-1214
55. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., Lee S.K., Shankar P., and Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448 (2007) 39-43. Successful and specific delivery of biological macromolecules of therapeutic potential through the blood-brain-barrier.
56. Shankar G., Pendley C., and Stein K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25 (2007) 555-561
57. Labrijn A.F., Aalberse R.C., and Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 20 (2008) 479-485
58. Deswal A., Bozkurt B., Seta Y., Parilti-Eiswirth S., Hayes F.A., Blosch C., and Mann D.L. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99 (1999) 3224-3226
59. Sutherland S. Peptibodies: the new cool technology. Drug Discov Today 9 (2004) 683
60. Blankenship J.W., Strobel S., Tan P., Grosmaire L., Simon A., Clark C., Bae G., Bader R., Espling E., Tamman J., et al. CD79BxDR SCORPION molecule: a single chain, bispecific immunotherapeutic with potent in vitro activity against B cell lymphoma. 2009 AACR Annual Meeting April 18-22; Denver, CO (2009)